newsfilter
← Latest News
GlobeNewswire·

Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in